Earnings summaries and quarterly performance for Sonoma Pharmaceuticals.
Executive leadership at Sonoma Pharmaceuticals.
Board of directors at Sonoma Pharmaceuticals.
Research analysts who have asked questions during Sonoma Pharmaceuticals earnings calls.
Bruce Jackson
The Benchmark Company LLC
2 questions for SNOA
Also covers: BFRI, BLTE, BSEM +8 more
EP
Eric Pansick
Private Investor
1 question for SNOA
JK
Jason Kolbert
D Boral Capital
1 question for SNOA
Also covers: BCDA, CANF, HUMA +6 more
Jason McCarthy
Maxim Group
1 question for SNOA
Also covers: BCLI, BRTX, CHRS +10 more
LE
Laura Engel
Stonegate Capital Partners
1 question for SNOA
LE
Laura Engle
Stonegate Securities
1 question for SNOA
RM
Raymond Myers
The Benchmark Company LLC
1 question for SNOA
SB
Scott Billeadeau
Walrus Partners
1 question for SNOA
Recent press releases and 8-K filings for SNOA.
Sonoma Pharmaceuticals, Inc. Files Investor Presentation Highlighting Recent Financial Performance and Business Developments
SNOA
Revenue Acceleration/Inflection
Product Launch
New Projects/Investments
- Sonoma Pharmaceuticals, Inc. filed an 8-K on January 12, 2026, attaching an updated investor presentation.
- The company reported strong financial performance for the three months ended September 30, 2025, with revenues increasing 57% and U.S. revenue growing 115% compared to the same period last year. Net loss per share also decreased 46% for the quarter.
- Sonoma, a global healthcare leader in stabilized hypochlorous acid (HOCl) products, has expanded its distribution network with new partnerships, including Medline Industries, LP in 2024 and WellSpring Pharmaceutical Corporation in 2025.
- Recent product introductions include an HOCl-based diaper rash product in August 2025 and the relaunch of several prescription and over-the-counter eye care and dermatology products in December 2024.
Jan 12, 2026, 1:30 PM
Sonoma Pharmaceuticals, Inc. Reports Strong Revenue Growth and Strategic Expansions
SNOA
Earnings
Product Launch
Revenue Acceleration/Inflection
- Sonoma Pharmaceuticals, Inc. reported strong financial performance, with revenues increasing 12% for the fiscal year ended March 31, 2025, and 18% for the three months ended June 30, 2025, compared to the same periods in the prior year, driven by a 57% increase in U.S. revenues in Q1 2026. Net loss and EBITDA loss also showed significant improvement.
- The company has expanded its market reach and distribution network through key partnerships, including agreements with Medline Industries, LP for wound care in the U.S. and Canada (August and October 2024) and WellSpring Pharmaceutical Corporation for sales to large U.S. retailers (starting January 2025). Sonoma also launched acne products in the UK in April 2025.
- Sonoma Pharmaceuticals continues to innovate and secure regulatory approvals for its hypochlorous acid (HOCl) products, launching an HOCl-based diaper rash product in August 2025, relaunching several prescription and OTC products in December 2024, and obtaining two new 510(k) clearances from the FDA in 2024. The company also successfully transitioned all commercialized products in Europe to the new EU Medical Device Regulation (MDR).
Sep 29, 2025, 8:30 PM
Quarterly earnings call transcripts for Sonoma Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more